Cardiovascular effects and safety of classic psychedelics.
Acile Nahlawi, Leon M Ptaszek, Jeremy N Ruskin
Nature cardiovascular research February 1, 2025 DOI: 10.1038/s44161-025-00608-2 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Citations | 15 |
| Key findings | Current evidence on the cardiovascular effects of classic psychedelics is limited and categorized into electrophysiological, structural, and vascular risks, with significant knowledge gaps requiring further investigation. |
Abstract
Psychedelics, used for millennia in spiritual and healing practices, have emerged as promising treatments for mental health conditions including depression, post-traumatic stress disorder (PTSD), substance use disorders and anxiety. Despite the therapeutic potential of psychedelics and their increasing use in both medical and nonmedical settings, there is a paucity of data on their cardiovascular safety. Here we review current evidence on the cardiovascular effects and safety of this unique class of therapeutic agents. The cardiovascular effects and associated risks of classic psychedelics are categorized into three areas: electrophysiological effects and arrhythmia risk, structural effects and valvular heart disease risk, and vascular effects including hypertension and ischemia risks. The Review also emphasizes crucial knowledge gaps that require further basic and clinical investigation including studies in individuals with underlying cardiovascular disease, characterization of important drug-drug interactions and studies on the safety of repetitive, long-term (including microdosing) exposure to classic psychedelics.
Citations in the library
Cited by 17
- A lexicon for psychedelic research and treatment Drug Science, Policy and Law September 1, 2025
- Reported Safety Practices of Publicly Advertised Psychedelic Retreats. JAMA Network Open January 2, 2026
- Psychedelics for Alcohol Use Disorder: A Narrative Review with Candidate Mechanisms of Action. CNS Drugs July 10, 2025
- The Causal Role of Consciousness in Psychedelic Therapy for Treatment-Resistant Depression: Hypothesis and Proposal ACS Pharmacology & Translational Science July 16, 2025
- The Role of Psychedelics in Contemporary Psychological and Interdisciplinary Inquiry. Journal of Personalized Medicine September 28, 2025
and 12 more in the library
Cites 74
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
and 69 more in the library